Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 177

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 177
---
 we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2021.

San Diego, California

March 27, 2025

115

Tyra Biosciences, Inc.

Balance Sheets

(in thousands, except share and per share data)

    December 31,

    December 31,

    2024

    2023

    Assets

    Current assets:

    Cash and cash equivalents
     
    $
    91,966

    $
    58,006

    Marketable securities

    249,475

    145,463

    Prepaid expenses and other current assets

    6,022

    8,202

    Total current assets

    347,463

    211,671

    Restricted cash

    1,000

    1,000

    Property and equipment, net

    1,651

    1,628

    Right-of-use assets

    6,068

    6,526

    Other long-term assets

    7,376

    5,032

    Total assets
     
    $
    363,558

    $
    225,857

    Liabilities and Stockholders’ Equity

    Current liabilities:

    Accounts payable
     
    $
    590

    $
    4,662

    Lease liabilities, current

    412

    280

    Accrued expenses and other current liabilities

    13,592

    10,391

    Total current liabilities

    14,594

    15,333

    Lease liabilities, noncurrent

    5,810

    6,216

    Other long-term liabilities

    3

    46

    Total liabilities

    20,407

    21,595

    Commitments and contingencies (Note 11)

    Stockholders’ equity:

    Preferred stock,